Navigation Links
Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R)
Date:5/7/2008

Agreement expands Dermagraft presence within government channels

WEST PORT, Conn., and SCOTTSDALE, Ariz., May 7 /PRNewswire/ -- Advanced BioHealing, Inc. (ABH) and Regenesis Biomedical, Inc. announced today an agreement focused on the promotion of Dermagraft(R) within the United States (US) government healthcare system. Under terms of the agreement Regenesis will provide its specialized sales force to market ABH's product Dermagraft within the Veteran's Administration (VA), Department of Defense (DOD), and TriCare healthcare payer systems.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008)

"Since launching Dermagraft in 2007, we have seen the need for a focused commercial presence within government healthcare systems," said Kevin Rakin, Chairman and CEO of Advanced BioHealing. "The management team at Regenesis has developed a corporate competency in promoting and distributing advanced wound care technology within these systems. We believe this co-promotion is the most effective way to maximize reach and penetration of Dermagraft in this specialized market."

Dermagraft is a bioengineered tissue product approved by the Food and Drug Administration (FDA) for the treatment of diabetic foot ulcers (DFUs). DFUs, a complication of diabetes, affect more than 400,000 people every year in the US. If not treated properly, DFUs can result in serious infection, sometimes resulting in the need for partial or full limb amputation. There are over 100,000 amputations performed annually in the US with more than 80% owing their origin to uncontrolled infection.

"There are many wound care companies that would enjoy the opportunity to promote a product like Dermagraft," says Virginia Rybski, Acting President of Regenesis Biomedical. "ABH has done a tremendous job in promoting the product in the traditional out-patient environment. We are pleased to have the opportunity for our sales and marketing team to bring this complementary product to veterans and soldiers who will benefit from treatment of their diabetic wounds." There are more than one hundred VA and DOD medical facilities within the US. They range in treatment capability from tertiary out-patient care for military veterans and soldiers to full service in-patient facilities.

Regenesis developed and now markets the Provant(R) Wound Therapy System. Provant delivers cell proliferation induction(R) (CPI(R)) therapy based on Regenesis' proprietary pulsed radio frequency energy (PRFE) core technology platform. PRFE uses an optimized radiofrequency signal to stimulate dormant cells, causing them to replicate and to produce natural growth factors and other gene expression products, which facilitate reduction of the pain and edema associated with post-operative wound healing in soft tissues.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities and providers that serve patients with wounds being treated by acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics. For more information about Regenesis Biomedical visit http://www.Regenesisbiomedical.com

About Advanced BioHealing, Inc.

Advanced BioHealing is an industry leader in the science of regenerative medicine. The Company is focused on the commercialization of cell-based and tissue-engineered products. It currently markets the FDA-approved product Dermagraft, for diabetic foot ulcers. Additionally, the Company's development pipeline includes a next-generation bioengineered tissue product which is in clinical trials. ABH is a privately held company with corporate offices in West Port, CT and manufacturing operations in La Jolla, CA. For more information about ABH visit http://www.AdvancedBioHealing.com

For more information about Dermagraft visit http://www.Dermagraft.com

Contacts:

Advanced BioHealing, Inc.

Dean Tozer

VP Marketing & Corporate Development

DTozer@AdvancedBioHealing.com

615-260-3770

Regenesis Biomedical, Inc.

Media: Scott Robey, VP Marketing robey@regenesisbiomedical.com

Clinicians: Rick Isenberg, MD, VP Clinical Affairs

isenberg@regenesisbiomedical.com

Investors: Virginia Rybski, Acting President

rybski@regenesisbiomedical.com

http://www.regenesisbiomedical.com

480-970-4970


'/>"/>
SOURCE Regenesis Biomedical, Inc.; Advanced BioHealing, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
2. Advanced Life Sciences Announces First Quarter 2008 Financial Results
3. Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast
4. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
5. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
6. Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements
7. Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin
8. Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
9. Advanced Life Sciences Receives Nasdaq Notification
10. Advanced Life Sciences Announces Fourth Quarter and Full Year 2007 Financial Results
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... In anticipation of AxioMed’s exclusive ... production, company President, Jake Lubinski will be traveling to Germany on December 6th. ... Cologne and Karlsruhe to discuss the benefits of a viscoelastic total disc replacement. ...
(Date:12/5/2016)... , Dec. 5, 2016  Eisai Inc. ... open-label two-year study of rufinamide, which were presented ... Epilepsy Society (AES) held from December 2-6 in ... final two-year safety, tolerability and cognitive data showed ... experienced similar safety and tolerability profiles, cognitive development ...
(Date:12/4/2016)... 2016  In five studies being presented today during ... and Exposition in San Diego , ... the delivery of life-saving treatments to patients with a ... to carry therapies directly to the sites in the ... a substantial advantage over traditional, systemic methods. The studies ...
(Date:12/2/2016)... Amgen (NASDAQ: AMGN ) and Allergan ... of a Marketing Authorization Application (MAA) to the European Medicines ... ® (bevacizumab). The companies believe this submission is the ... "The submission of ABP 215 to the EMA is ... portfolio," said Sean E. Harper , M.D., executive vice ...
Breaking Biology Technology:
(Date:11/30/2016)... -- higi SH llc (higi) announced today the launch ... industry thought-leaders and celebrity influencers looking to encourage, ... steps to live healthier, more active lives. ... built the largest self-screening health station network in ... have conducted over 185 million biometric screenings.  The ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by ... Component (Hardware and Software), Function (Contact and Non-contact), Application, and Region - ... grow from USD 10.74 Billion in 2015 to reach USD 32.73 Billion ... Continue Reading ... ...
Breaking Biology News(10 mins):